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The relationship between cell proliferation, Cl− secretion, and
renal cyst growth: A study using CFTR inhibitors.
Background. In autosomal-dominant polycystic kidney dis-
ease (ADPKD), cAMP-stimulated cell proliferation and Cl−
secretion via the cystic fibrosis transmembrane conductance
regulator (CFTR) Cl− channel drive the enlargement of fluid-
filled epithelial cysts. To investigate how CFTR blockers inhibit
cyst growth, we studied cAMP-dependent Cl− secretion, cell
proliferation, and cyst growth using type I Madin Darby canine
kidney (MDCK) cells as a model of renal cyst development and
growth.
Methods. We grew MDCK cysts in collagen gels in the
presence of the cAMP agonist forskolin, measured Cl− se-
cretion with the Ussing chamber technique, and assayed
cell proliferation using nonpolarized and polarized MDCK
cells. To inhibit CFTR, we used glibenclamide, 5-nitro-2-(3-
phenylpropylamino)-benzoic acid (NPPB), genistein, and the
specific CFTR inhibitor CFTRinh-172. As controls, we tested
the effects of blockers of other types of apical membrane Cl−
channels and inhibitors of basolateral membrane ion channels
and transporters.
Results. In the absence of inhibitors of transepithelial ion
transport, forskolin stimulated dramatic cyst growth. CFTR
blockers and inhibitors of basolateral membrane ion channels
and transporters retarded cyst growth. In contrast, blockers of
other types of apical membrane Cl− channels, which were with-
out effect on CFTR, failed to inhibit cyst growth. Inhibition of
cyst growth by CFTR blockers was correlated with inhibition
of cAMP-stimulated Cl− current (correlation coefficient = 0.81;
P < 0.05), but not cell proliferation (correlation coefficient =
0.50; P > 0.05).
Conclusion. Our data suggest that CFTR blockers might re-
tard cyst growth predominantly by inhibiting fluid accumulation
within the cyst lumen.
Autosomal-dominant polycystic kidney disease
(ADPKD) is one of the most prevalent single gene
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disorders to affect humans, with an incidence of ap-
proximately 1 in 1000 live births in all ethnic groups [1].
The disease is caused by mutations in the polycystin
proteins that initiate a cascade of events that result in
the formation of multiple fluid-filled epithelial cysts
[2, 3]. The insidious enlargement of cysts progressively
destroys the architecture of the kidney, leading to severe
renal failure. At present, there are no cures for ADPKD,
which accounts for approximately 8% to 10% of patients
requiring kidney transplantation and dialysis [1].
The development and growth of ADPKD cysts involve
the proliferation of immature epithelial cells, changes in
the extracellular matrix, and the accumulation of fluid
within the cyst cavity [2, 3]. The growth of ADPKD
cysts is accelerated by activation of the cAMP signal-
transduction cascade, with elevation of the intracellular
concentration of cAMP stimulating the proliferation of
ADPKD epithelial cells [4, 5] and fluid accumulation
within the cyst cavity [3, 6]. The accumulation of fluid
within ADPKD cysts is powered by transepithelial Cl−
movements that resemble cAMP-stimulated Cl− secre-
tion by secretory epithelia, such as those that line the
respiratory airways, pancreatic ducts, and small intes-
tine [3, 7]. In secretory epithelia, the cystic fibrosis trans-
membrane conductance regulator (CFTR) Cl− channel
located in the apical membrane provides a pathway for
Cl− exit from the cell, and controls the rate of transep-
ithelial fluid and electrolyte transport [7]. Malfunction of
CFTR causes the genetic disease cystic fibrosis (CF) [7].
Several lines of evidence suggest that the CFTR Cl−
channel plays a key role in the accumulation of fluid
and electrolytes within the lumen of ADPKD cysts. First,
immunocytochemistry studies demonstrated that CFTR
is located in the apical membrane of ADPKD cysts [8,
9]. Second, Cl− currents with properties and regula-
tion identical to those of CFTR have been identified in
ADPKD epithelial cells using the whole-cell patch-clamp
technique [9]. Third, CFTR antisense oligonucleotides
inhibited cAMP-stimulated fluid secretion by ADPKD
epithelia [10]. Taken together, these data suggest that
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Cl− transport by CFTR drives the accumulation of fluid
within the lumen of ADPKD cysts. They also suggest
strongly that inhibitors of the CFTR Cl− channel might
retard cyst growth by blocking fluid accumulation within
the cyst lumen.
However, other lines of evidence suggest that in-
hibitors of the CFTR Cl− channel might diminish cyst
growth by retarding cell proliferation. First, blockers of
a variety of ion channels, including the volume-regulated
anion channel (VRAC), inhibit cell division [11, 12]. Sec-
ond, in addition to its best-characterized role as a regu-
lated Cl− channel, CFTR modulates the activity of other
ion channels and transporters in epithelial cells, includ-
ing VRACs and volume-sensitive K+ channels [7, 13, 14].
Third, expression of wild-type CFTR in CF lymphocytes
restored the cell-cycle-dependence of Cl− permeability
in these cells [15]. These data raise the possibility that
inhibitors of the CFTR Cl− channel might retard cyst
growth by inhibiting cell proliferation.
Thus, the aim of this study was to test the effects of in-
hibitors of the CFTR Cl− channel on cyst growth and
identify their mechanism of action. For this work, we
used type I Madin Darby canine kidney (MDCK) ep-
ithelial cells, a valuable model system to investigate renal
cyst development and growth [3]. These cells endoge-
nously express CFTR, form polarized epithelia on
permeable filter supports, and cysts in collagen gels
[16, 17]. To inhibit CFTR, we used the sulfonylurea
drug glibenclamide, the arylaminobenzoate 5-nitro-2-(3-
phenylpropylamino)-benzoic acid (NPPB), the flavonoid
genistein, the thiazolidinone CFTRinh-172, and H-89, a
membrane-permeant selective inhibitor of protein ki-
nase A (PKA). Glibenclamide and NPPB are open-
channel blockers of the CFTR Cl− channel that inhibit
Cl− flow through the CFTR pore [18, 19]. Genistein is
widely used to potentiate CFTR Cl− currents (for review,
see [20]). However, elevated concentrations of the drug
inhibit CFTR by disrupting channel gating [21]. CFTRinh-
172 is a potent, specific inhibitor of the CFTR Cl− chan-
nel that was identified by high-throughput screening [22].
Like genistein [21], CFTRinh-172 inhibits CFTR by alter-
ing channel gating [23]. H-89 inhibits CFTR by imped-
ing PKA-dependent phosphorylation, a prerequisite for
channel opening [7, 24]. As controls, we tested the ef-
fects on cyst growth of inhibitors of other types of api-
cal membrane Cl− channels and blockers of basolateral
membrane ion channels and transporters. In this way, we
could establish the importance of different types of ion
channels and transporters for cyst growth.
METHODS
Cells and cell culture
Type I MDCK epithelial cells [16] were a generous gift
from Professor M.J. Welsh (University of Iowa, Iowa City,
IA, USA). Cells were cultured in MDCK media (a 1:1
mixture of Dulbecco’s modified Eagle medium (DMEM)
and Ham’s F-12 nutrient medium supplemented with
10% fetal bovine serum (FBS), 100 U mL−1 penicillin,
and 100 lg mL−1 streptomycin (all from Invitrogen, Ltd.,
Paisley, UK) at 37◦C in a humidified atmosphere of 5%
CO2.
Cyst growth
To grow cysts, MDCK cells were cultured in collagen
gels in the presence of the cAMP agonist forskolin us-
ing a modification of the method of Grantham et al [17].
Individual wells of a 24-well plate containing 0.4 mL of
ice-cold Vitrogen (∼3.0 mg mL−1 collagen; Cohe-
sion Technologies, Inc., Palto Alto, CA, USA) supple-
mented with 10% (v/v) 10× minimum essential medium,
10 mmol/L HEPES, 27 mmol/L NaHCO3, 100 U mL−1
penicillin, and 100 lg mL−1 streptomycin (pH 7.4 with
NaOH) were seeded with ∼800 MDCK cells. After gela-
tion of the Vitrogen, 1.5 mL of MDCK media containing
forskolin (10 lmol/L) was added to each well of the 24-
well plate. Plates were maintained at 37◦C in a humidified
atmosphere of 5% CO2, and the MDCK media contain-
ing forskolin changed every two days.
Six days after seeding collagen gels with MDCK cells,
cysts were readily detected at ×100 magnification using
an inverted microscope with phase contrast optics (Leica,
model DMIL, Milton Keynes, UK). To test the effect of
drugs on cyst growth, drugs were added to MDCK media
in the continued presence of forskolin on day six. MDCK
media containing forskolin and drugs was changed every
two days for a total period of six days. Photographs of
individual cysts were taken before the addition of drugs
and at two-day intervals over the duration of the experi-
ment. To identify individual cysts, each cyst was assigned
a unique reference number using a grid placed below the
24-well plate.
In some experiments, we tested the effects of CFTRinh-
172 on cyst formation by adding the drug to MDCK media
in the continued presence of forskolin from day 0 onward.
At day six we compared the number and volume of cysts
grown in the absence and presence of CFTRinh-172.
Cyst number and volume measurements
To determine cyst numbers, we counted all cysts in each
well that had a diameter larger than 50 lm on day six. To
calculate cyst volumes, the diameter of cysts was mea-
sured directly from photographs of cysts using images
that had been magnified by identical amounts. By assum-
ing that cysts are spherical in shape, we calculated cyst
volume (4/3 × p × r3).
Ussing chamber experiments
To grow MDCK cells as polarized epithelia, cells
were seeded directly onto permeable filter supports
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(Millicell-PCF culture plate inserts, 0.4 lm pore size,
12 mm diameter, Millipore Corp.; Fisher Scientific UK,
Loughborough, UK) at a density of 3 × 105 cells per 0.6
cm2. Every second day after seeding, we changed the
MDCK media and measured transepithelial resistance
(Rt) using an epithelial voltohmmeter (EVOM; World
Precision Instruments, Stevenage, UK). On day eight
(when Rt = 2.2 ± 0.2 k; mean ± SEM; N = 40), we
removed the media from the apical side of the epithelium
to form an air-liquid interface because this maneuver en-
hances the expression of CFTR at the apical membrane
of MDCK epithelia [16]. On day 10 (when Rt = 5.0 ± 0.3
k; N = 40), we used MDCK epithelia for experiments.
To test the effects of drugs on Cl− channels located in
the apical membrane, we permeabilized the basolateral
membrane with nystatin, clamped transepithelial volt-
age at 0 mV, and imposed a large Cl− concentration
gradient across the epithelium. Under these condi-
tions, we measured apical Cl− current (IClapical) using
a Warner Instrument Corp. Epithelial Voltage-Clamp
(model EC-825; Harvard Apparatus, Ltd., Edenbridge,
UK) and AxoScope data acquisition and analysis soft-
ware (version 8.2, Axon Instruments, Inc., Union City,
CA, USA). MDCK epithelia were mounted in modi-
fied Ussing chambers (Warner Instrument Corp., Dual
Channel Chamber, model U-2500; Harvard Apparatus
Ltd.). The basolateral membrane of MDCK epithelia
was bathed in a solution containing (mmol/L): 140 NaCl,
5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3 CaCl2, 0.5 MgCl2,
10 HEPES, and 4.2 NaHCO3, pH 7.2 with Tris ([Cl−],
149 mmol/L); osmolarity, 292 ± 0.4 mOsm (N = 9). The
composition of the solution bathing the apical membrane
of MDCK epithelia was identical to that of the basolat-
eral solution, with the exception that 133.3 mmol/L Na
gluconate + 2.5 mmol/L NaCl and 5 mmol/L K gluconate
replaced 140 mmol/L NaCl and 5 mmol/L KCl, respec-
tively, to give a Cl− concentration of 14.8 mmol/L (osmo-
larity, 282 ± 0.3 mOsm; N = 9). To compensate for the
Ca2+ buffering capacity of gluconate, we increased the
concentration of Ca2+ to 5.7 mmol/L in the apical solu-
tion; all solutions were maintained at 37◦C and bubbled
with O2.
To permeabilize the basolateral membrane to mono-
valent ions, we added nystatin (0.36 mg/mL) to the
basolateral solution. The effectiveness of nystatin per-
meabilization was assessed as previously described [25].
We clamped transepithelial voltage (referenced to the
basolateral solution) at 0 mV, and recorded IClapical con-
tinuously using a Digidata 1200 interface (Axon Instru-
ments, Inc.) and AxoScope software at a sampling rate
of 0.5 kHz. To measure Rt, we applied 5 mV voltage
steps (duration 0.1 seconds, period 10 seconds), and then
calculated Rt using Ohm’s law. The resistance of the fil-
ter and solutions, in the absence of cells, was subtracted
from all measurements. Flow of current from the ba-
solateral to the apical solution is shown as an upward
deflection.
To test the effects of drugs on basolateral membrane
ion channels and transporters, we measured short-circuit
current (Isc) as described for IClapical, with the excep-
tion that the basolateral membrane was intact. Dur-
ing prolonged recordings of IClapical or Isc, rundown
of cAMP-stimulated Cl− current was observed. For
example, 2500 seconds after stimulation by forskolin
(10 lmol/L), IClapical declined by 19% ± 6% (N = 6). To
compensate for current rundown when quantifying drug
inhibition, we subtracted from the drug-induced current
inhibition an amount of current equivalent to that of the
rundown observed at the specific time point used to de-
termine current inhibition.
Cell proliferation assays
Nonpolarized cells. To test the effect of drugs on the
proliferation of MDCK cells, we used cells grown in
MDCK media containing either 0.01% or 10% FBS. For
these experiments, we used MDCK cells grown in media
containing 5% FBS and 1% insulin-transferrin-selenium-
X supplement (ITS-X; Invitrogen, Ltd.). On day −1, 3.5 ×
104 MDCK cells were seeded in individual wells of a 12-
well plate containing MDCK media with 1% FBS and 1%
ITS-X supplement. On day 0, the concentration of FBS
was either reduced further to 0.01%, or increased to 10%
and forskolin (10 lmol/L) and drugs were added to the
MDCK media. MDCK media containing forskolin and
drugs was changed every two days for a total period of six
days. To determine the number of cells per well, MDCK
cells were harvested using trypsin (0.25% wt/vol), cen-
trifuged at 1200 rpm for 5 minutes, and resuspended in
1 mL of MDCK media before counting using a hemocy-
tometer. The viability of MDCK cells was determined by
staining with trypan blue (0.2%).
Polarized cells. For cell proliferation assays using po-
larized MDCK epithelia, we seeded cells directly onto
transparent permeable filter supports (Transwell-clear in-
sert, 0.4 lm pore size, 12 mm diameter, Corning, Ltd.,
High Wycombe, UK) at a density of 3 × 105 cells per 1.1
cm2 using media with 5% FBS, 1% ITS-X supplement,
and forskolin (10 lmol/L). Every day, we measured Rt
using an EVOM, and on every second day, we changed
the MDCK media. On day five (when Rt = 1.1 ± 0.1 k;
N = 27), we reduced the concentration of FBS to 1%.
On day six, we further reduced the FBS concentration to
0.01% and added drugs to the media. After measuring
Rt, we removed the media from the apical side of the
epithelium to form an air-liquid interface for the reasons
described above. MDCK media containing forskolin and
drugs were changed every two days for a total period of
six days. To determine the number of cells per filter, cells
were harvested and counted, as described above.
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Lactate dehydrogenase assay. For cytotoxicity studies,
we used a nonradioactive cytotoxicity detection kit that
measures the activity of lactate dehydrogenase (LDH)
released from cells (Roche Products, Ltd., Welwyn Gar-
den City, UK). We grew MDCK cells as described above
for cell proliferation studies of nonpolarized MDCK cells,
with the exception that cells were grown in 96-well plates
(Corning, Ltd.) using a seeding density of 8 × 102 cells
per well. Cells were treated with drugs for 24 hours in
the presence of 0.01% FBS and 1% ITS-X supplement
before performing the LDH assay according to the man-
ufacturer’s instructions.
Analysis of the relationships between cyst growth, Cl−
secretion, and cell proliferation
To compare the potency of the drugs on cyst growth,
Cl− secretion, and cell proliferation, we designated val-
ues in the presence of forskolin (10 lmol/L), but absence
of drugs, as 100%. We then expressed values in the pres-
ence of drugs as a percentage of those in the presence
of forskolin alone. To investigate correlations between
different groups of data, we used Pearson’s correlation
test.
Reagents
Barium, bumetanide, 4,4′-diisothiocyanatostilbene-
2,2′-disulfonic acid (DIDS), forskolin, genistein,
glibenclamide, HEPES, niflumic acid, nystatin, ouabain,
tamoxifen, and tetraethylammonium (TEA) chloride
were purchased from the Sigma-Aldrich Company,
Ltd. (Poole, UK). NPPB was obtained from Semat
Technical (UK) Ltd. (St. Albans, UK), and H-89 (N-[2-
((p-Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfon-
amide, 2HCl; Calbiochem) was purchased from Merck
Biosciences, Ltd. (Nottingham, UK). Calix[4]arene was
a generous gift of Professor R.J. Bridges and Dr. A.K.
Singh (University of Pittsburgh, Pittsburgh, PA, USA).
CFTRinh-172 was a generous gift of Professor A.S.
Verkman (University of California, San Francisco, CA,
USA). All other chemicals were of reagent grade.
Forskolin was dissolved in methanol, tamoxifen in
ethanol and barium, calix[4]arene and TEA in distilled
water; all other drugs were dissolved in DMSO. Stock
solutions were stored at −20◦C and diluted in either
MDCK media or physiologic salt solutions to achieve fi-
nal concentrations immediately before use. Precautions
against light-sensitive reactions were observed when us-
ing bumetanide, genistein, nystatin, ouabain, tamoxifen,
and TEA. DMSO (0.4% v/v) and ethanol (0.2% v/v)
were without effect on cyst growth, cell proliferation, and
IClapical (data not shown).
Statistics
Results are expressed as mean ± SEM of N observa-
tions. To test for differences between groups of data, we
used Student t test. Differences were considered statis-
tically significant when P < 0.05. Tests were performed
using SigmaStatTM (version 2.03, Jandel Scientific GmbH,
Erkrath, Germany).
RESULTS
Inhibitors of transepithelial ion transport diminish cyst
growth
To test the effects of inhibitors of the CFTR Cl− chan-
nel on cyst growth, we used type I MDCK cells that
form cysts when grown in collagen gels in the presence
of cAMP agonists [17]. Following the seeding of collagen
gels with MDCK cells and incubation in media containing
forskolin (10 lmol/L), we first observed cysts after 2 to 3
days. Cysts progressively increased in size and, after six
days, they were readily detected at ×100 magnification
(Fig. 1A). Figure 1A and B demonstrates that in the sus-
tained presence of forskolin (10 lmol/L), cysts continued
to enlarge over the following six days. During this pe-
riod, cyst volume increased by 687 ± 50% (day 6, 0.0019
± 0.0003; day 12, 0.0094 ± 0.0012 mm3; N = 186; P <
0.01; Student paired t test; Fig. 2). Based on these data,
we examined the effects of inhibitors of the CFTR Cl−
channel on cyst growth between day 6 and 12 after seed-
ing collagen gels with MDCK cells.
To inhibit the CFTR Cl− channel, we used CFTRinh-
172 (10 lmol/L), genistein (100 lmol/L), glibenclamide
(100 lmol/L), H-89 (10 lmol/L), and NPPB (50 lmol/L).
Glibenclamide and NPPB are open-channel blockers
of CFTR that inhibit Cl− flow through the channel,
CFTRinh-172 and genistein are allosteric blockers of
CFTR that disrupt channel gating, and H-89 is an in-
hibitor of PKA that phosphorylates CFTR prior to chan-
nel opening [7, 18, 19, 21, 23, 24]. As controls, we tested
the effects on cyst growth of drugs that inhibit other
types of apical membrane Cl− channels and blockers
of ion channels and transporters that are located in the
basolateral membrane of epithelia [7, 26]. To inhibit
other types of apical membrane Cl− channels, we used
calix[4]arene (10 lmol/L), DIDS (200 lmol/L), niflumic
acid (100 lmol/L) and tamoxifen (10 lmol/L). DIDS
inhibits other types of epithelial Cl− channels, but is
without effect on CFTR when added to the outside of
cells [26]. Niflumic acid inhibits Ca2+-activated Cl− chan-
nels, tamoxifen inhibits VRACs, and calix[4]arene in-
hibits outwardly rectifying Cl− channels [27] [abstract;
Singh AK et al, Pediatr Pulmonol 13(Suppl):237, 1996].
At the concentrations used, calix[4]arene is without ef-
fect on CFTR [abstract; Singh AK et al, Pediatr Pulmonol
13(Suppl):237, 1996], while tamoxifen and niflumic
acid inhibit CFTR activity by 10% and 25%, respec-
tively [28, 29]. To inhibit ion channels and transporters in
the basolateral membrane, we used barium (1 mmol/L),
bumetanide (100 lmol/L), ouabain (1 lmol/L), and TEA
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Fig. 1. Photomicrographs of cysts. The images show cysts before (A, C, E, G, and I) and after (B, D, F, H, and J) treatment with blockers of
transepithelial ion transport in the presence of forskolin (10 lmol/L). Forskolin (Fk, 10 lmol/L) (A and B), CFTRinh-172 (C172; 10 lmol/L) (C and
D), niflumic acid (NFA; 100 lmol/L) (E and F), bumetanide (But; 100 lmol/L) (G and H), and DIDS (200 lmol/L) (I and J). Photomicrographs
were taken on day six after seeding gels (A, C, E, G, and I) and day 12 after seeding gels (B, D, F, H, and J). Bar = 200 lm.
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Fig. 2. Time course of cyst growth in the pres-
ence of blockers of transepithelial ion trans-
port. Data show the relationship between
cyst volume and time for CFTR blockers:
CFTRinh-172 (C172; 10 lmol/L; N = 141),
genistein (Gen, 100 lmol/L; N = 34), gliben-
clamide (Glib, 100 lmol/L; N = 26), NPPB
(50 lmol/L; N = 22), and H-89 (10 lmol/L; N
= 36) (A); inhibitors of other types of apical
membrane Cl− channels: calix[4]arene (Clx,
10 lmol/L; N = 31), DIDS (200 lmol/L; N =
32), niflumic acid (NFA, 100 lmol/L; N = 39),
and tamoxifen (Tam, 10 lmol/L; N = 39) (B);
blockers of basolateral membrane ion chan-
nels and transporters: barium (Ba; 1 mmol/L;
N = 30), bumetanide (But, 100 lmol/L; N =
24), ouabain (Ouab, 1 lmol/L; N = 25), and
TEA (10 mmol/L; N = 30) (C). In A to C,
filled circles show the effect of forskolin (Fk,
10 lmol/L; N = 186) on cyst growth. Data
are expressed as a percentage of the value
at day six, and are mean ± SEM of N ob-
servations, where N is the number of cysts.
Different drugs were tested in the presence of
forskolin (10 lmol/L) in at least three differ-
ent experiments. Where not shown, error bars
are smaller than symbol size.
(10 mmol/L). Bumetanide inhibits the Na+-K+-2Cl− co-
transporter, ouabain inhibits the Na+-K+ ATPase, while
barium and TEA inhibit many different types of K+ chan-
nels.
Figure 1 shows images of cysts grown in the absence
and presence of drugs from different classes of transport
inhibitors, while Figure 2 quantifies the effects of drugs
on cyst growth. Figure 1C and D and Figure 2A demon-
strate that inhibitors of the CFTR Cl− channel dimin-
ished the enlargement of cysts. After six days of treatment
with CFTRinh-172 (10 lmol/L), genistein (100 lmol/L),
glibenclamide (100 lmol/L), H-89 (10 lmol/L) and NPPB
(50 lmol/L), the volumes of cysts were significantly
smaller than those treated with forskolin alone (day
12 data: P < 0.01; Student unpaired t test; Fig. 2A).
Figure 1E, F, I, and J and Figure 2B show that block-
ers of other types of apical membrane Cl− channels had
variable effects on cyst growth. After six days treatment,
niflumic acid (100 lmol/L) and tamoxifen (10 lmol/L)
diminished (day 12 data: P < 0.01), while calix[4]arene
(10 lmol/L) and DIDS (200 lmol/L) were without effect
(day 12 data: P > 0.05). Figure 1G and H and Figure 2C
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demonstrate that inhibitors of basolateral membrane ion
channels and transporters diminished the enlargement of
cysts with variable potency. After four days of treatment,
ouabain (1 lmol/L) caused the disappearance of cysts
(Fig. 2C). After six days of treatment, barium (1 mmol/L),
bumetanide (100 lmol/L), and TEA (10 mmol/L) inhib-
ited cyst growth (day 12 data: bumetanide, P < 0.01; bar-
ium and TEA, P < 0.05; Fig. 2C). These data suggest
that blockers of CFTR and basolateral membrane ion
channels and transporters inhibit cyst growth. They also
suggest that drugs that block apical membrane Cl− chan-
nels have variable effects on cyst growth, with those drugs
that are without effect on the CFTR Cl− channel failing
to inhibit cyst growth.
Effects of the specific CFTR inhibitor CFTRinh-172 on
cyst formation
The observation that CFTR blockers diminish cyst
growth suggests that these drugs might also inhibit cyst
formation. To test this possibility, we grew cysts in the con-
tinuous presence of the specific CFTR inhibitor CFTRinh-
172 (10 lmol/L) from day 0 onward. Figure 3A and B
show images of cysts grown in the absence and presence
of CFTRinh-172 (10 lmol/L) at day six, and Figure 3C
and D quantify data for cyst volume and number. The
data demonstrate that CFTRinh-172 decreased not only
the volume of individual cysts, but also the number of
cysts formed. These data suggest that CFTRinh-172 might
inhibit both the formation and growth of renal cysts.
Effects of inhibitors of transepithelial ion transport on
cAMP-stimulated Cl− current in MDCK epithelia
To evaluate the effects of drugs on fluid accumulation
within cysts, we employed the Ussing chamber technique
to record cAMP-stimulated Cl− current, a measure of
transepithelial Cl− secretion. To enhance the magnitude
of cAMP-stimulated Cl− current, we grew MDCK epithe-
lia at an air-liquid interface to augment the cell surface
expression of CFTR [16]. In addition, we clamped
transepithelial voltage at 0 mV, and imposed a large Cl−
concentration gradient across epithelia to magnify the
size of cAMP-stimulated Cl− current. For studies of drugs
that inhibit Cl− channels located in the apical membrane,
the basolateral membrane was permeabilized with nys-
tatin (0.36 mg/mL). However, for studies of drugs that
inhibit basolateral membrane ion channels and trans-
porters, the basolateral membrane was intact.
Figure 4A demonstrates that addition of forskolin
(10 lmol/L) to the apical and basolateral solutions gen-
erated large Cl− currents in nystatin-permeabilized ep-
ithelia (IClapical, 70 ± 8 lA cm−2; N = 69; Fig. 4A, left
and center), but small Cl− currents in intact epithelia
(Isc, 27 ± 2 lA cm−2; N = 16; Fig. 4A, right). Fol-
lowing the activation of cAMP-stimulated Cl− current,
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Fig. 3. The specific CFTR inhibitor CFTRinh-172 inhibits the forma-
tion of MDCK cysts. (A and B) are images of MDCK cysts grown in
collagen gels in the presence of forskolin (10 lmol/L) on day six af-
ter seeding the gel with MDCK cells. Control (A), cyst grown in the
continuous presence of CFTRinh-172 (10 lmol/L) (B). (C and D) show
volume and number of cysts formed in the absence and presence of
CFTRinh-172 (10 lmol/L). Data are mean ± SEM (N = 23–186 cysts
from 4–23 wells) made on day six. Asterisks indicate values that are
significantly different from controls (P < 0.05).
we added blockers of CFTR and other types of apical
membrane Cl− channels to the apical solution, and in-
hibitors of basolateral membrane ion channels and trans-
porters to the basolateral solution. Figure 4 demonstrates
that blockers of the CFTR Cl− channel caused a signif-
icant reduction of cAMP-stimulated Cl− current (P <
0.01; Student paired t test). With the exception of ni-
flumic acid (100 lmol/L; P < 0.01), blockers of other
types of apical membrane Cl− channels failed to inhibit
cAMP-stimulated Cl− current (P > 0.05; Fig. 4). With
the exception of TEA (10 mmol/L), inhibitors of basolat-
eral membrane ion channels and transporters decreased
cAMP-stimulated Cl− current (Fig. 4). However, the re-
duction was only statistically significant for bumetanide
(100 lmol/L; P < 0.01; N = 5). These data suggest that
inhibition of CFTR-mediated fluid accumulation might
account for some of the effects of drugs on cyst growth.
Inhibition of cell proliferation by blockers of
transepithelial ion transport
In addition to fluid accumulation within the cyst lu-
men [3, 6], the growth of renal cysts involves cAMP-
stimulated cell proliferation [4, 5]. To learn whether
blockers of transepithelial ion transport also inhibit the
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Fig. 4. Effect of blockers of transepithe-
lial ion transport on cAMP-stimulated Cl−
current in MDCK epithelia. Representative
recordings show the effects of CFTRinh-
172 (10 lmol/L), DIDS (200 lmol/L),
and bumetanide (100 lmol/L) on cAMP-
stimulated Cl− current (A). To test the ef-
fects of CFTRinh-172 and DIDS, we recorded
IClapical after the basolateral membrane was
permeabilized with nystatin (0.36 mg/mL),
whereas to test the effect of bumetanide, we
recorded Isc with the basolateral membrane
intact. Transepithelial voltage was clamped
at 0 mV, and there was a large Cl− concen-
tration gradient across the epithelium (baso-
lateral [Cl−], 149 mmol/L; apical [Cl−], 14.8
mmol/L). At the times indicated by the arrows
labeled Fk, forskolin (10 lmol/L) was added
to both the apical and basolateral solutions.
At the times indicated by the other arrows,
CFTRinh-172 (10 lmol/L) and DIDS (200
lmol/L) were added to the apical solution,
and bumetanide (100 lmol/L) was added to
the basolateral solution. Inhibition of cAMP-
stimulated Cl− current by CFTR blockers, in-
hibitors of other types of apical membrane
Cl− channels, and blockers of basolateral
membrane ion channels and transporters (B).
Data show the magnitude of current inhibi-
tion by CFTRinh-172 (10 lmol/L; N = 5),
genistein (100 lmol/L; N = 5), glibenclamide
(100 lmol/L; N = 5), H-89 (10 lmol/L; N = 4),
NPPB (50 lmol/L; N = 5), calix[4]arene (10
lmol/L; N = 5), DIDS (200 lmol/L; N = 5),
niflumic acid (100 lmol/L; N = 8), tamoxifen
(10 lmol/L; N = 5), barium (1 mmol/L; N = 4),
bumetanide (100 lmol/L; N = 5), ouabain (1
lmol/L; N = 5) and TEA (10 mmol/L; N = 6).
Data are mean ± SEM of N observations mea-
sured once inhibition had reached steady state
(e.g., bumetanide) or 3500 seconds after cur-
rent activation (e.g., CFTRinh-172). The dot-
ted line indicates the control value before the
addition of drugs. The asterisks indicate val-
ues of current inhibition that are significantly
different from the control value (P < 0.01).
growth of MDCK cysts by retarding cell proliferation,
we investigated the effects of drugs on the proliferation
of nonpolarized MDCK cells in the presence of forskolin
(10 lmol/L).
Figure 5A, C, and E shows the time course of cell
proliferation in the absence and presence of forskolin
(10 lmol/L) and blockers of transepithelial ion transport
using MDCK media containing 0.01% FBS. In contrast
to ADPKD cells [4, 5], forskolin was without effect on
the proliferation of MDCK cells. In both the absence
and presence of forskolin, the number of MDCK cells
increased dramatically over a six-day period with very
similar time courses (Fig. 5A).
After six days of treatment in the presence of forskolin,
with the exception of H-89 (10 lmol/L), blockers of the
CFTR Cl− channel potently inhibited the proliferation of
MDCK cells (day 6 data: P < 0.01; Student unpaired t test;
Fig. 5A). Similarly, with the exception of calix[4]arene
(10 lmol/L), blockers of other types of apical membrane
Cl− channels potently inhibited cell proliferation (day 6
data: P < 0.01; Student unpaired t test; Fig. 5C). How-
ever, inhibitors of basolateral membrane ion channels
and transporters retarded cell proliferation with variable
potency. Figure 5E demonstrates that ouabain (1 lmol/L)
dramatically inhibited cell proliferation (P < 0.01), bar-
ium (1 mmol/L) and TEA (10 mmol/L) slowed (day 6
data: P < 0.01), but bumetanide (100 lmol/L) was with-
out effect on cell proliferation (day 6 data: P > 0.05).
Our data indicate that many, but not all blockers of
transepithelial ion transport inhibit the proliferation of
nonpolarized MDCK cells in the presence of 0.01% FBS
and forskolin (10 lmol/L). As controls, we performed
several additional experiments. First, we used FBS (10%)
because this was the FBS concentration in the media em-
ployed for cyst growth studies, and because FBS is known
to alter both the rate of cell proliferation and the effects
of drugs [11, 30]. Figure 5B, D, and F shows the time
course of cell proliferation in the absence and presence
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Fig. 5. Effects of blockers of transepithelial ion transport on the pro-
liferation of nonpolarized MDCK cells. Data show the relationship be-
tween cell proliferation and time for blockers of transepithelial ion
transport using MDCK media containing 0.01% FBS (A, C, and E)
and 10% FBS (B, D, and F). CFTR blockers (A and B): CFTRinh-172
(10 lmol/L; N = 4), genistein (100 lmol/L; N = 4), glibenclamide (100
lmol/L; N = 4), NPPB (50 lmol/L; N = 4), and H-89 (10 lmol/L; N = 4).
Inhibitors of other types of apical membrane Cl− channels (C and D):
calix[4]arene (10 lmol/L; N = 4), DIDS (200 lmol/L; N = 4), niflumic
acid (100 lmol/L; N = 4), and tamoxifen (10 lmol/L; N = 4). Block-
ers of basolateral membrane ion channels and transporters (E and F):
barium (1 mmol/L; N = 4), bumetanide (100 lmol/L; N = 4), ouabain
(1 lmol/L; N = 4), and TEA (10 mmol/L; N = 4). The open circles in
(A) and (B) and the filled circles (A to F) show cell proliferation in the
absence (control, C; N = 4-6) and presence of forskolin (Fk; 10 lmol/L;
N = 7-8), respectively. Data are mean ± SEM of N observations, where
N is the number of wells of cells. Other details as in Figure 2.
of forskolin (10 lmol/L) and blockers of transepithelial
ion transport using MDCK media containing 10% FBS.
Under these conditions, forskolin (10 lmol/L) retarded
cell proliferation (day 6 data: P < 0.01; Student unpaired
t test; Fig. 5B). When compared with the 0.01% FBS
data, with the exception of H-89 (10 lmol/L), genistein
(100 lmol/L), barium (1 mmol/L), TEA (10 mmol/L), and
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Fig. 6. Cell proliferation in polarized epithelia and cytotoxicity of
drugs. Time course of cell proliferation in polarized MDCK epithe-
lia in the absence and presence of glibenclamide (100 lmol/L), NPPB
(50 lmol/L); calix[4]arene (10 lmol/L), and bumetanide (100 lmol/L)
(A). Data are mean ± SEM (N = 5), where N is the number of epithelia.
Different drugs were tested in at least two different experiments in the
presence of forskolin (10 lmol/L). Other details as in Figure 2. Cytotox-
icity of transepithelial ion transport inhibitors (B). Data show the re-
lease of LDH from nonpolarized MDCK cells grown in the absence and
presence of CFTR blockers (genistein, 100 lmol/L; glibenclamide, 100
lmol/L; NPPB, 50 lmol/L), blockers of other types of apical membrane
Cl− channels (DIDS, 200 lmol/L; niflumic acid, 100 lmol/L; tamoxifen,
10 lmol/L), and inhibitors of basolateral membrane ion channels and
transporters (ouabain, 1 lmol/L; TEA, 10 mmol/L). All inhibitors of
transepithelial ion transport were tested in the presence of forskolin
(10 lmol/L). Data are mean ± SEM (control, C, and forskolin, Fk, 10
lmol/L; N = 9; all other drugs N = 6). The asterisks indicate values
that are significantly increased compared with the forskolin value (P <
0.01).
ouabain (1 lmol/L), all the blockers inhibited MDCK cell
proliferation less potently in the presence of 10% FBS
(Fig. 5B, D, and F). The weakening of inhibition of cell
proliferation was especially pronounced for CFTRinh-
172 (10 lmol/L; Fig. 5B). Moreover, calix[4]arene
(10 lmol/L) and bumetanide (100 lmol/L) stimulated the
proliferation of MDCK cells (day 6 data: P < 0.01; Stu-
dent unpaired t test; Fig. 5D and F).
Second, we tested the effects of blockers of transep-
ithelial ion transport on MDCK cell proliferation in
the absence of forskolin and presence of 0.01% FBS.
With the exception of DIDS (100 lmol/L) and tamox-
ifen (10 lmol/L), which were without effect, all the drugs
tested inhibited cell proliferation with similar potency
to that observed in the presence of forskolin (data not
shown).
Third, we tested the effects of some drugs on MDCK
epithelia grown on permeable filter supports in the pres-
ence of 0.01% FBS. Once MDCK epithelia developed a
high Rt (indicative of a polarized epithelium), we mon-
itored the effects of drugs on cell proliferation in the
presence of forskolin (10 lmol/L) over a six-day period.
Figure 6A shows that the number of cells increased slowly
in the presence of forskolin (10 lmol/L). They also show
that glibenclamide (100 lmol/L) and NPPB (50 lmol/L)
potently inhibited cell proliferation in polarized epithe-
lia (day 6 data: P < 0.01; Student unpaired t test), while
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bumetanide (100 lmol/L) and calix[4]arene (10 lmol/L)
were without effect (day 6 data: P > 0.05; Fig. 6A). These
data suggest that the effects of drugs on cell proliferation
were not affected by cell polarity.
Finally, to test whether drugs that inhibited cell pro-
liferation cause cell damage and death, we measured
LDH release from nonpolarized MDCK cells cultured
with 0.01% FBS for 24 hours in the absence and pres-
ence of forskolin and drugs. Figure 6B demonstrates that
forskolin (10 lmol/L) was without effect on LDH re-
lease from MDCK cells (P > 0.05; Student unpaired
t test). Moreover, glibenclamide (100 lmol/L), NPPB
(50 lmol/L), niflumic acid (100 lmol/L), tamoxifen
(10 lmol/L), and TEA (10 mmol/L) did not increase the
release of LDH from MDCK cells compared with that
observed in the presence of forskolin (P > 0.05; Fig. 6B).
Only genistein (100 lmol/L), DIDS (200 lmol/L), and
ouabain (1 lmol/L) augmented the release of LDH from
MDCK cells (P < 0.05; Fig. 6B). These data suggest that
blockers of the CFTR Cl− channel might slow the prolif-
eration of MDCK cells in the presence of forskolin with-
out causing significant cytotoxic effects.
Relationship between cAMP-dependent cyst growth, cell
proliferation, and Cl− current
Our data suggest that inhibitors of the CFTR Cl− chan-
nel diminish cyst growth by retarding both Cl− secre-
tion and cell proliferation. To evaluate this possibility, we
examined cyst enlargement, Cl− current, and cell prolif-
eration in the presence of different inhibitors of transep-
ithelial ion transport. Figure 7A demonstrates that cyst
enlargement and cAMP-stimulated Cl− current were well
correlated in the presence of CFTR blockers (Pearson’s
correlation coefficient = 0.81; r2 = 0.66; P < 0.05). Similar
results were observed with all the drugs tested (Pearson’s
correlation coefficient = 0.69; r2 = 0.49; P < 0.01; Fig. 7A).
Figure 7B shows that cyst enlargement and cell prolifera-
tion (in the presence of 0.01% FBS) were not well corre-
lated (CFTR blockers, Pearson’s correlation coefficient
= 0.44; r2 = 0.19; P > 0.05; all drugs tested, Pearson’s
correlation coefficient = 0.43; r2 = 0.19; P > 0.05). Fi-
nally, Figure 7C demonstrates that cyst enlargement and
cell proliferation (in the presence of 10% FBS) were not
well correlated for CFTR blockers (Pearson’s correla-
tion coefficient = 0.50; r2 = 0.25; P > 0.05), but were well
correlated for all the drugs tested (Pearson’s correlation
coefficient = 0.64; r2 = 0.39; P < 0.05). These data suggest
that CFTR blockers might retard cyst growth predomi-
nantly by inhibiting fluid accumulation within the cyst
lumen.
DISCUSSION
The aim of our study was to test the effects of inhibitors
of the CFTR Cl− channel on renal cyst growth, and
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Fig. 7. Inhibition of cyst growth is correlated with inhibition of Cl− cur-
rent, but not inhibition of cell proliferation. Correlation between cyst
enlargement and cAMP-stimulated Cl− current (A). Correlation be-
tween cyst enlargement and cell proliferation in the presence of 0.01%
FBS (B). Correlation between cyst enlargement and cell proliferation
in the presence of 10% FBS (C). Key: 1, CFTRinh-172 (10 lmol/L);
2, genistein (25 lmol/L); 3, genistein (100 lmol/L); 4, glibenclamide
(100 lmol/L); 5, H-89 (10 lmol/L); 6, NPPB (50 lmol/L); 7, NPPB
(400 lmol/L); 8, calix[4]arene (10 lmol/L); 9, DIDS (200 lmol/L); 10,
niflumic acid (100 lmol/L); 11, tamoxifen (10 lmol/L); 12, barium (1
mmol/L); 13, bumetanide (100 lmol/L); 14, ouabain (1 lmol/L); and
15, TEA (10 mmol/L). Open squares represent CFTR blockers and
filled circles denote other blockers of transepithelial ion transport. The
continuous lines and the dotted lines show the fits of first-order regres-
sions to all the data and to the data for the CFTR blockers, respectively.
Data are mean ± SEM (cyst growth, N = 20-141; Cl− current, N = 5-8;
cell proliferation, N = 4).
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identify their mechanism of action. For this purpose, we
employed a battery of 12 inhibitors of transepithelial ion
transport, including blockers of the CFTR Cl− channel,
inhibitors of other types of apical membrane Cl− chan-
nels, and blockers of basolateral membrane ion channels
and transporters. Using these agents, we investigated cyst
growth, cAMP-stimulated Cl− currents, and cell prolifer-
ation.
To test the effects of drugs on renal cyst growth, we
employed type I MDCK cells. We chose MDCK cells be-
cause ADPKD tissue is scarce and difficult to culture,
whereas MDCK cells are abundant and stable in cul-
ture [3]. However, type I MDCK cells are heterogeneous.
For example, Orellana and Marfella-Scivittaro [31] iden-
tified four different clones of MDCK cells with variable
cAMP responsiveness and distinct morphologic pheno-
types. Like ADPKD cells [3, 4, 32], our MDCK cells
form cysts in collagen gels and generate polarized ep-
ithelia with cAMP-stimulated Cl− currents when grown
on permeable filter supports. However, our MDCK cells
differ from ADPKD cells in at least one important re-
spect. Cyclic AMP agonists inhibit the proliferation of
our MDCK cells, but stimulate that of ADPKD cells [4,
5]. Despite this difference, our MDCK cells are a valu-
able model system to examine the effects of inhibitors of
transepithelial ion transport on renal cyst growth.
Using MDCK cells subcultured from a single cyst,
Grantham et al [17] first demonstrated that agents that
inhibit transepithelial ion transport retard cyst enlarge-
ment. The most potent inhibitors identified were ouabain
and amiloride analogs that inhibit Na+/Ca2+ exchange
[17]. More recent studies have investigated the role of api-
cal Cl− channels and basolateral membrane K+ channels
in renal cyst growth. Hanaoka and Guggino [4] exam-
ined the effects of DIDS, diphenylamine-2-carboxylate
(DPC), and glibenclamide on the growth of ADPKD
cysts, while Sullivan et al [32] tested the hypothesis that
glibenclamide retards the growth of ADPKD cysts by
inhibiting ATP-sensitive K+ channels located in the ba-
solateral membrane of ADPKD epithelial cells. Impor-
tantly, these and other studies [8–10] raise the possibility
that inhibitors of the CFTR Cl− channel might diminish
cyst growth.
In the present study, we demonstrate that all drugs
that inhibit Cl− transport by CFTR retard cyst growth.
These drugs include agents that directly inhibit the CFTR
Cl− channel by either open-channel (e.g., glibenclamide
[18]), or allosteric (e.g., genistein [21]) mechanisms. They
also include agents that act indirectly either by inhibiting
cAMP-dependent phosphorylation of CFTR (e.g., H-89
[24]), or by interfering with basolateral membrane ion
channels and transporters that accumulate Cl− within ep-
ithelial cells (e.g., bumetanide [33]). In contrast, DIDS
and calix[4]arene, two drugs that inhibit other types of
apical membrane Cl− channels, but which are without
effect on CFTR [26] [abstract; Singh AK et al, Pedi-
atr Pulmonol 13(Suppl):237, 1996] failed to inhibit cyst
growth. Similarly, Zn2+ (100 lmol/L), which blocks CLC-
2, a member of the CLC family of voltage-gated Cl− chan-
nels that is abundantly expressed in the kidney [27], was
without effect on cyst growth (data not shown). The re-
maining blockers of other types of apical membrane Cl−
channels tested, tamoxifen and niflumic acid, inhibited
cyst growth. However, these drugs are known to block
the CFTR Cl− channel [28, 29], raising the possibility
that they inhibit cyst growth, at least in part, by blocking
the CFTR Cl− channel. Importantly, CFTRinh-172, a po-
tent, specific blocker of the CFTR Cl− channel, retarded
cyst formation and diminished cyst growth. We interpret
our data to suggest that the CFTR Cl− channel and ba-
solateral membrane ion channels and transporters play
key roles in renal cyst growth. Importantly, comparison
of our data with previous work [4, 32] suggests that the
pharmacology of cyst growth is similar in ADPKD and
MDCK cells.
Previous work suggests that blockers of transepithe-
lial ion transport diminish cyst enlargement by inhibit-
ing fluid accumulation and/or cell proliferation [17, 32].
To investigate how CFTR inhibitors retard cyst enlarge-
ment, we examined cAMP-stimulated Cl− secretion and
cell proliferation.
To specifically examine the effects of drugs on apical
membrane Cl− channels, we adopted a strategy similar
to that of Anderson and Welsh [25]. These authors inves-
tigated the different type of apical membrane Cl− chan-
nels in airway and intestinal epithelia by permeabilizing
the basolateral membrane with nystatin and imposing a
large Cl− concentration gradient across the epithelium
[25]. An advantage of this approach is that the effects of
inhibitors are more clearly observed when the magnitude
of cAMP-stimulated Cl− current is larger. Moreover, by
employing a Cl− concentration gradient, we mimicked
the condition of gradient ADPKD cysts, which, like type
I MDCK cells, are derived from the distal tubule [3]. Our
data demonstrate that blockers of the CFTR Cl− chan-
nel inhibit cAMP-stimulated Cl− current. In contrast,
with the exception of niflumic acid (for discussion, see
above), blockers of other types of apical membrane Cl−
channels were without effect. Consistent with our data,
Mangoo-Karim et al [33] demonstrated that DPC, an ary-
laminobenzoate that inhibits CFTR with low affinity [20],
attenuates cAMP-stimulated Isc in MDCK epithelia.
CFTRinh-172 was the most potent inhibitor of cAMP-
stimulated Cl− currents among the drugs that we tested.
However, the potency of CFTRinh-172 observed in the
present study is much less than that demonstrated by Ma
et al [22]. A likely explanation for this difference is the
rundown of cAMP-stimulated Cl− currents in MDCK
epithelia, which was pronounced over the prolonged
time intervals required for CFTRinh-172 to fully exert its
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effects. When we corrected data for this rundown, the po-
tency of CFTR blockers was reduced, while blockers of
other types of apical membrane Cl− channels appeared
to potentiate cAMP-stimulated Cl− current. A similar
explanation might account for our failure to observe in-
hibition of cAMP-stimulated Cl− currents with ouabain,
barium, and TEA. Alternatively, the use of a large Cl−
concentration gradient might attenuate the inhibitory
effects of these blockers. Consistent with this latter
idea, when we bathed MDCK epithelia in symmet-
ric NaCl-rich solutions, both ouabain and TEA inhib-
ited cAMP-stimulated Cl− currents, and the potency of
bumetanide was increased [inhibition of ICl: bumetanide
(100 lmol/L), 85 ± 6% (N = 7); ouabain (1 lmol/L), 58 ±
5% (N = 4), and TEA (10 mmol/L), 37 ± 13% (N = 5)].
Cyclic AMP agonists stimulate the proliferation of
ADPKD epithelial cells [4, 5]. Therefore, we tested the
effects of inhibitors of transepithelial ion transport on the
proliferation of MDCK cells in the presence of forskolin.
In contrast to the effects of forskolin on ADPKD epithe-
lial cells, forskolin failed to stimulate the proliferation of
our MDCK cells. One possible explanation for this result
is that our MDCK cells endogenously generate high lev-
els of intracellular cAMP to the extent that further stim-
ulation by forskolin fails to augment cell proliferation.
However, our observation that the PKA inhibitor H-89
was without effect on the proliferation of MDCK cells in
the presence of 0.01% FBS argues against this possibil-
ity. Instead, our MDCK cells are reminiscent of normal
human kidney cortex epithelial cells in which cAMP is
either without effect or inhibits cell proliferation [4, 5].
An explanation for the effects of cAMP on the growth
of MDCK cells is provided by the work of Yamada et al
[34]. These authors suggest that cAMP inhibits the prolif-
eration of MDCK cells by blocking the mitogenic effects
of MAP kinases [34].
Blockers of K+ channels inhibit cell proliferation by
interfering with cell cycle progression [11]. In contrast,
less is known about the effects of CFTR blockers on
cell proliferation. In this study, we demonstrated that the
CFTR blockers CFTRinh-172, genistein, glibenclamide,
and NPPB inhibit the proliferation of MDCK cells, and
that the inhibitory effects were FBS-dependent. Two
possible explanations for the effects of FBS are (1) FBS
contains a variety of growth factors that stimulate cell
proliferation [30], and (2) proteins in FBS might bind
drugs to reduce their effective concentration [11]. Our ob-
servation that glibenclamide and NPPB caused the num-
ber of cells in MDCK epithelia to decrease to zero after
four days of treatment suggests that these drugs either
have cytotoxic effects or cause the detachment of MDCK
cells from permeable filter supports. However, our stud-
ies using the LDH release assay argue that these drugs
are without significant cytotoxic effects, a conclusion sup-
ported by previous work [35, 36]. Although our data
do not reveal the targets with which glibenclamide and
NPPB interact to inhibit cell proliferation, they suggest
that these drugs retard cell cycle progression in MDCK
cells. Consistent with this idea, these drugs have been
demonstrated to arrest cancer cells at the G0/G1 stage of
the cell cycle [12, 35].
Our data suggest that CFTR blockers diminish cyst
growth by inhibiting both cAMP-stimulated Cl− current
and cell proliferation. To try to determine the relative
importance of these effects of CFTR blockers for renal
cyst growth, we performed a correlation test. We found
that inhibition of cyst growth by CFTR blockers was cor-
related with inhibition of cAMP-stimulated Cl− current,
but not cell proliferation. Differences in the efficacy with
which drugs inhibit cyst growth, cAMP-stimulated Cl−
current, and cell proliferation might be caused by a num-
ber of factors. These include (1) testing the effects of drugs
on electrolyte transport using voltage-clamped epithelia,
(2) using nonpolarized rather than polarized cells to ex-
amine the effects of drugs on cell proliferation, and (3)
with the exception of CFTRinh-172, the lack of specificity
of the CFTR blockers tested. Despite these differences,
our data suggest that fluid accumulation within the cyst
lumen plays an important role in cyst enlargement. For
example, DIDS, a drug that inhibited cell proliferation,
but not cAMP-stimulated Cl− current, failed to retard
cyst growth. In contrast, bumetanide, a drug that inhib-
ited cAMP-stimulated Cl− current, but not cell prolifer-
ation, diminished cyst enlargement. Finally, the specific
CFTR inhibitor CFTRinh-172, which inhibited cAMP-
stimulated Cl− current more potently than cell prolif-
eration, led to the formation of small cysts with thick
walls (Fig. 1; for discussion see [17]). Thus, our data pro-
vide a cellular explanation for the effects of drugs on cyst
growth.
The accessibility of basolateral membrane ion chan-
nels and transporters located on the outside (gel-facing)
membrane of renal cysts explains why drugs that inhibit
these ion channels and transporters diminish cyst growth.
At first sight, the location of CFTR on the apical (lumen-
facing) membrane of renal cysts argues that the CFTR
Cl− channel is an unsuitable target for drugs designed
to retard cyst growth. However, knowledge of transep-
ithelial Cl− secretion and the molecular pharmacology of
CFTR suggest otherwise (Fig. 8) [7, 20].
CFTR blockers are large organic anions [20]. When
added to the outside of cysts, they enter epithelial cells by
crossing the lipid phase of the basolateral membrane by
nonionic diffusion. Once inside epithelial cells, the elec-
trochemical gradient that drives transepithelial Cl− secre-
tion sweeps CFTR blockers toward the apical membrane,
where they interact with CFTR. In contrast to other ep-
ithelial Cl− channels [37], CFTR possesses a deep, wide
intracellular vestibule, where open-channel blockers bind
to occlude the channel pore and inhibit Cl− permeation
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Fig. 8. Mechanism of inhibition of cyst growth by blockers of CFTR-
driven Cl− secretion. Model of Cl− secretion by cyst-lining epithe-
lial cells (A). Chloride movements drive fluid accumulation within the
cyst lumen. Fluid accumulation causes cyst enlargement (1) directly
by swelling cysts, and (2) indirectly by stretching cells (denoted by
double-headed arrows) to promote cell division. Sites of inhibition
of CFTR-driven Cl− secretion (B). Different inhibitors of basolateral
membrane ion channels and transporters and their targets are indi-
cated. (In ADPKD epithelia, glibenclamide inhibits ATP-sensitive K+
channels in the basolateral membrane and CFTR Cl− channels in the
apical membrane [32]). Open-channel blockers of CFTR (large organic
anions; denoted by A−) occlude the intracellular end of the CFTR
pore to prevent Cl− permeation. For clarity, only a model of the CFTR
pore is shown. Genistein interacts with the nucleotide-binding domains
to interfere with CFTR channel gating [21, 40]. The binding site of
CFTRinh-172 is currently unknown. See text and [7] for further details.
[18, 20]. Importantly, the interaction of open-channel
blockers with CFTR is both voltage-dependent and sen-
sitive to the external Cl− concentration (for discussion,
see [20]). Because of the basolateral to apical driving
force for transepithelial Cl− secretion, once open-channel
blockers bind within the CFTR pore, they are likely to
be difficult to dislodge. As a result, fluid accumulation
within the cyst cavity is inhibited and cyst growth retarded
(Fig. 8).
A potential link between CFTR-driven transepithelial
Cl− secretion and cell proliferation in MDCK cysts is
provided by the work of Tanner et al [38]. These authors
demonstrated that stretching cysts stimulates DNA syn-
thesis in MDCK cells. This suggests that by attenuating
fluid accumulation within the cyst lumen, CFTR block-
ers might inhibit the proliferation of MDCK cells (Fig. 8).
Alternatively, CFTR blockers might inhibit the function
of CFTR as a regulator of cell cycle progression [15]. By
analogy with the human EAG K+ channel [39], CFTR
might alter its biophysical properties during the cell cycle
to control cell volume. Alternatively, CFTR might regu-
late cell cycle progression by controlling the activity of
the ion channels and transporters that regulate cell vol-
ume. Consistent with this latter idea, Vennekens et al [13]
showed that CFTR attenuates the activity of VRACs by
a mechanism independent of CFTR activation by cAMP-
dependent phosphorylation. Thus, CFTR blockers might
inhibit cell proliferation by blocking the actions of CFTR
as a channel regulator.
CONCLUSION
The goal of this study was to investigate the effects of
blockers of the CFTR Cl− channel on renal cyst growth
and identify their mechanism of action. Using type I
MDCK cells as a model of cyst development and growth,
we demonstrated that CFTR blockers and inhibitors of
basolateral membrane ion channels and transporters re-
tard cyst growth. By examining the effects of drugs on
transepithelial Cl− secretion and cell growth, we showed
that CFTR blockers retard cyst growth principally by in-
hibiting transepithelial Cl− secretion, not cell prolifera-
tion.
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